MAS vs PCSA · P/E 18, rev $7.83B vs $5.9M cap
Masco Corporation (MAS) versus Processa Pharmaceuticals Inc (PCSA) — a side-by-side from cached financials, not a winner call.
Masco Corporation (MAS) is a building products & equipment company listed on US.
Processa Pharmaceuticals Inc (PCSA) is a biotechnology company listed on NASDAQ.
Latest reported MAS revenue for 2024-12-31 was $7.83B. Net income was $874.0M. Revenue was down 1.7% from 2023-12-31 to 2024-12-31. MAS currently screens at market cap $14.00B and trailing P/E 18.1.
Latest reported PCSA revenue for 2023-09-30 was $0. Net income was -$2.1M. PCSA currently screens at market cap $5.9M.
MAS currently screens at market cap $14.00B and trailing P/E 18.1. PCSA currently screens at market cap $5.9M.
Not investment advice. Open the MAS and PCSA stock pages for the full models.
Not investment advice.